Trade War Tangles: Stocks to Watch as Tariffs Tighten!
The stock market on April 28, 2025, is a cauldron of tension as U.S.-China trade negotiations falter, sending ripples across global markets. The S&P 500 closed at 5,525.21 last Friday, up 0.74%, capping a four-day rally, but futures today are down 0.2%, hinting at a cautious start. The Nasdaq Composite soared 1.26% to 17,482.94 on April 25, driven by tech gains, yet trade uncertainty looms large. With earnings season in full swing, let’s dive into the market’s pulse, pinpoint stocks to watch, and uncover trading opportunities amid the chaos. Market Dynamics: Trade Tensions and Earnings Clash The S&P 500’s recent rally faces a test as U.S.-China trade talks hit a wall. China’s partial tariff rollback on U.S. semiconduc
⬆ $Protalix BioTherapeutics (PLX)$ - Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/plx-first-quarter-update?utm_source=tiger_community By Zacks Small Cap Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/zacks-small-cap-research?utm_source=tiger_community On Protalix BioTherapeutics (PLX):- https://www.smartkarma.com/entities/protalix-biotherapeutics-inc?utm_source=tiger_community
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.